Mammalian  	Mammalian  	 JJ	B-NP
target  	target  	 NN	I-NP
of  	of  	 IN	I-NP
rapamycin 	rapamycin 	 NNS	I-NP
:  	:  	 :	O
discovery  	discovery  	 NN	O
of  	of  	 IN	O
rapamycin  	rapamycin  	 NN	B-NP
reveals  	reveals  	 VBZ	O
a  	a  	 DT	O
signaling  	signaling  	 JJ	O
pathway  	pathway  	 JJ	O
important  	important  	 JJ	O
for  	for  	 IN	O
normal  	normal  	 JJ	O
and  	and  	 CC	O
cancer  	cancer  	 NN	B-NP
cell  	cell  	 NN	I-NP
growth  	growth  	 NN	I-NP
Since  	Since  	 IN	O
the  	the  	 DT	O
discovery  	discovery  	 NN	O
of  	of  	 IN	O
rapamycin 	rapamycin 	 NN	B-NP
,  	,  	 ,	O
considerable  	considerable  	 JJ	O
progress  	progress  	 NN	O
has  	has  	 VBZ	O
been  	been  	 VBN	O
made  	made  	 VBN	O
in  	in  	 IN	O
unraveling  	unraveling  	 VBG	O
the  	the  	 DT	O
details  	details  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
mammalian  	mammalian  	 JJ	B-NP
target  	target  	 NN	I-NP
of  	of  	 IN	I-NP
rapamycin  	rapamycin  	 NNS	I-NP
( 	( 	 -LRB-	O
mTOR 	mTOR 	 NNP	B-NP
)  	)  	 -RRB-	O
signaling  	signaling  	 VBG	B-NP
network 	network 	 NN	I-NP
,  	,  	 ,	O
including  	including  	 VBG	O
the  	the  	 DT	O
upstream  	upstream  	 JJ	O
mechanisms  	mechanisms  	 NNS	O
that  	that  	 WDT	O
modulate  	modulate  	 VBP	O
mTOR  	mTOR  	 JJ	B-NP
signaling  	signaling  	 JJ	I-NP
functions 	functions 	 NNS	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
the  	the  	 DT	O
roles  	roles  	 NNS	O
of  	of  	 IN	O
mTOR  	mTOR  	 JJ	O
in  	in  	 IN	O
the  	the  	 DT	O
regulation  	regulation  	 NN	O
of  	of  	 IN	O
mRNA  	mRNA  	 JJ	B-NP
translation  	translation  	 NN	I-NP
and  	and  	 CC	O
other  	other  	 JJ	O
cell  	cell  	 NN	O
growth-related  	growth-related  	 NNP	O
responses.  	responses.  	 NNP	O
mTOR  	mTOR  	 NNP	B-NP
is  	is  	 VBZ	O
found  	found  	 VBN	O
in  	in  	 IN	O
two  	two  	 CD	O
different  	different  	 JJ	O
complexes  	complexes  	 NNS	O
within  	within  	 IN	O
the  	the  	 DT	O
cell 	cell 	 NN	O
,  	,  	 ,	O
mTORC1  	mTORC1  	 NNP	B-NP
and  	and  	 CC	O
mTORC2 	mTORC2 	 NNP	B-NP
,  	,  	 ,	O
but  	but  	 CC	O
only  	only  	 JJ	O
mTORC1  	mTORC1  	 NN	B-NP
is  	is  	 VBZ	O
sensitive  	sensitive  	 JJ	O
to  	to  	 TO	O
inhibition  	inhibition  	 VB	O
by  	by  	 IN	O
rapamycin.  	rapamycin.  	 NNP	B-NP
mTORC1  	mTORC1  	 NNP	O
is  	is  	 VBZ	O
a  	a  	 DT	O
master  	master  	 NN	B-NP
controller  	controller  	 NN	I-NP
of  	of  	 IN	I-NP
protein  	protein  	 NN	I-NP
synthesis 	synthesis 	 NN	I-NP
,  	,  	 ,	O
integrating  	integrating  	 VBG	B-NP
signals  	signals  	 NNS	I-NP
from  	from  	 IN	O
growth  	growth  	 NN	B-NP
factors  	factors  	 NNS	I-NP
within  	within  	 IN	O
the  	the  	 DT	O
context  	context  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
energy  	energy  	 NN	B-NP
and  	and  	 CC	O
nutritional  	nutritional  	 JJ	B-NP
conditions  	conditions  	 NNS	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
cell 	cell 	 NN	O
.  	.  	 .	O
Activated  	Activated  	 NNP	B-NP
mTORC1  	mTORC1  	 NNP	I-NP
regulates  	regulates  	 VBZ	O
protein  	protein  	 JJ	B-NP
synthesis  	synthesis  	 NN	I-NP
by  	by  	 IN	O
directly  	directly  	 RB	O
phosphorylating  	phosphorylating  	 CD	O
4E-binding  	4E-binding  	 CD	B-NP
protein  	protein  	 CD	I-NP
1  	1  	 CD	I-NP
( 	( 	 -LRB-	O
4E-BP1 	4E-BP1 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
p70S6K  	p70S6K  	 NNP	O
( 	( 	 -LRB-	O
S6K 	S6K 	 NNP	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
translation  	translation  	 JJ	B-NP
initiation  	initiation  	 NN	I-NP
factors  	factors  	 NNS	I-NP
that  	that  	 WDT	O
are  	are  	 VBP	O
important  	important  	 JJ	O
to  	to  	 TO	O
cap-dependent  	cap-dependent  	 JJ	B-NP
mRNA  	mRNA  	 JJ	I-NP
translation 	translation 	 NN	I-NP
,  	,  	 ,	O
which  	which  	 WDT	O
increases  	increases  	 VBZ	O
the  	the  	 DT	O
level  	level  	 NN	O
of  	of  	 IN	O
many  	many  	 JJ	O
proteins  	proteins  	 NNS	O
that  	that  	 WDT	O
are  	are  	 VBP	O
needed  	needed  	 VBN	O
for  	for  	 IN	O
cell  	cell  	 NN	O
cycle  	cycle  	 NN	O
progression 	progression 	 NN	O
,  	,  	 ,	O
proliferation 	proliferation 	 NN	B-NP
,  	,  	 ,	O
angiogenesis 	angiogenesis 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
survival  	survival  	 NN	B-NP
pathways 	pathways 	 NN	I-NP
.  	.  	 .	O
In  	In  	 IN	O
normal  	normal  	 JJ	B-NP
physiology 	physiology 	 NN	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
roles  	roles  	 NNS	O
of  	of  	 IN	O
mTOR  	mTOR  	 JJ	O
in  	in  	 IN	O
both  	both  	 DT	O
glucose  	glucose  	 NN	B-NP
and  	and  	 CC	O
lipid  	lipid  	 JJ	B-NP
catabolism  	catabolism  	 NNS	I-NP
underscore  	underscore  	 VBP	O
the  	the  	 DT	O
importance  	importance  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
mTOR  	mTOR  	 JJ	B-NP
pathway  	pathway  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
production  	production  	 NN	O
of  	of  	 IN	O
metabolic  	metabolic  	 JJ	B-NP
energy  	energy  	 NN	I-NP
in  	in  	 IN	O
quantities  	quantities  	 NNS	O
sufficient  	sufficient  	 JJ	O
to  	to  	 TO	O
fuel  	fuel  	 VB	O
cell  	cell  	 NN	B-NP
growth  	growth  	 NN	I-NP
and  	and  	 CC	O
mitotic  	mitotic  	 JJ	B-NP
cell  	cell  	 NN	I-NP
division 	division 	 NN	I-NP
.  	.  	 .	O
Several  	Several  	 JJ	O
oncogenes  	oncogenes  	 NNS	B-NP
and  	and  	 CC	O
tumor-suppressor  	tumor-suppressor  	 JJ	B-NP
genes  	genes  	 NNS	I-NP
that  	that  	 WDT	O
activate  	activate  	 VBP	O
mTORC1 	mTORC1 	 RB	O
,  	,  	 ,	O
often  	often  	 RB	O
through  	through  	 IN	O
the  	the  	 DT	O
phosphatidylinositol  	phosphatidylinositol  	 JJ	B-NP
3-kinase  	3-kinase  	 NNP	I-NP
( 	( 	 -LRB-	O
PI3K 	PI3K 	 NNP	B-NP
) 	) 	 -RRB-	O
/ 	/ 	 NNP	O
AKT  	AKT  	 NNP	B-NP
pathway 	pathway 	 NN	I-NP
,  	,  	 ,	O
are  	are  	 VBP	O
frequently  	frequently  	 RB	O
dysregulated  	dysregulated  	 VBN	O
in  	in  	 IN	O
cancer 	cancer 	 NN	O
.  	.  	 .	O
Novel  	Novel  	 NN	O
analogs  	analogs  	 NN	O
of  	of  	 IN	O
rapamycin  	rapamycin  	 NNS	B-NP
( 	( 	 -LRB-	O
temsirolimus 	temsirolimus 	 UH	B-NP
,  	,  	 ,	O
everolimus 	everolimus 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
deforolimus 	deforolimus 	 CD	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
which  	which  	 WDT	O
have  	have  	 VBP	O
improved  	improved  	 VBN	O
pharmaceutical  	pharmaceutical  	 JJ	B-NP
properties 	properties 	 NNS	I-NP
,  	,  	 ,	O
were  	were  	 VBD	O
designed  	designed  	 VBN	O
for  	for  	 IN	O
oncology  	oncology  	 JJ	B-NP
indications 	indications 	 NNS	I-NP
.  	.  	 .	O
Clinical  	Clinical  	 JJ	B-NP
trials  	trials  	 NNS	I-NP
of  	of  	 IN	O
these  	these  	 DT	O
analogs  	analogs  	 NNS	O
have  	have  	 VBP	O
already  	already  	 RB	O
validated  	validated  	 VB	O
the  	the  	 DT	O
importance  	importance  	 NN	O
of  	of  	 IN	O
mTOR  	mTOR  	 JJ	B-NP
inhibition  	inhibition  	 NN	I-NP
as  	as  	 IN	O
a  	a  	 DT	O
novel  	novel  	 NN	O
treatment  	treatment  	 NN	O
strategy  	strategy  	 NN	O
for  	for  	 IN	O
several  	several  	 JJ	O
malignancies 	malignancies 	 NN	O
.  	.  	 .	O
Inhibition  	Inhibition  	 NNP	O
of  	of  	 IN	O
mTOR  	mTOR  	 JJ	O
now  	now  	 RB	O
represents  	represents  	 VBZ	O
an  	an  	 DT	O
attractive  	attractive  	 JJ	O
anti-tumor  	anti-tumor  	 JJ	B-NP
target 	target 	 NN	I-NP
,  	,  	 ,	O
either  	either  	 CC	O
alone  	alone  	 RB	O
or  	or  	 CC	O
in  	in  	 IN	O
combination  	combination  	 NN	O
with  	with  	 IN	O
strategies  	strategies  	 NNS	O
to  	to  	 TO	O
target  	target  	 VB	O
other  	other  	 JJ	O
pathways  	pathways  	 NN	O
that  	that  	 WDT	O
may  	may  	 MD	O
overcome  	overcome  	 VB	O
resistance 	resistance 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
far-reaching  	far-reaching  	 JJ	O
downstream  	downstream  	 JJ	O
consequences  	consequences  	 NNS	B-NP
of  	of  	 IN	I-NP
mTOR  	mTOR  	 JJ	I-NP
inhibition  	inhibition  	 NNS	I-NP
make  	make  	 VBP	O
defining  	defining  	 VBG	O
the  	the  	 DT	O
critical  	critical  	 JJ	B-NP
molecular  	molecular  	 JJ	I-NP
effector  	effector  	 JJ	I-NP
mechanisms  	mechanisms  	 NNS	I-NP
that  	that  	 WDT	O
mediate  	mediate  	 VBZ	O
the  	the  	 DT	O
anti-tumor  	anti-tumor  	 JJ	B-NP
response  	response  	 NN	I-NP
and  	and  	 CC	O
associated  	associated  	 JJ	O
biomarkers  	biomarkers  	 NN	B-NP
that  	that  	 WDT	O
predict  	predict  	 VBP	O
responsiveness  	responsiveness  	 VBN	O
to  	to  	 TO	O
mTOR  	mTOR  	 JJ	B-NP
inhibitors  	inhibitors  	 NNS	I-NP
a  	a  	 DT	O
challenge  	challenge  	 NN	O
and  	and  	 CC	O
priority  	priority  	 NN	O
for  	for  	 IN	O
the  	the  	 DT	O
field 	field 	 NN	O
.  	.  	 .	O
